Allergy Therapeutics plc has disclosed a Form 8.5 (EPT/RI) from Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The form provides key information regarding dealings in Allergy Therapeutics' securities. The dealings were undertaken on September 29, 2023. The form includes details of purchases and sales of the company's 0.1p ordinary shares, with 82,603 shares purchased at a highest price of 0.0148 per unit and 50,000 shares sold at a price of 0.01598 per unit. No cash-settled derivative transactions or stock-settled derivative transactions were reported. The form also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities, options, or derivatives. The contact person for this disclosure is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969.